Return to Trial Database

BTCRC-BRE18-337

Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337

Status

Enrollment Closed

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial BTCRC-BRE18-337 being conducted in.

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center